BioNTech's Tübingen Exit Falls Through as BNT113 Data Keeps Investors Waiting
Published on 10/16/2026 at 11:50 | Editorial boerse-global.de
BioNTech is navigating a stretch that tests the patience of even its most committed shareholders. The Mainz-based company, now valued at EUR 20.99 billion, is pushing ahead with its transformation into a broad-based oncology developer, yet operational adjustments and mixed signals from the laboratory are arriving at the same time. For investors, the central question is how sturdy the pipeline really is — and how much more time the science will demand.
A Trial That Hasn't Finished Talking
At the heart of the current debate sits BNT113, the company's candidate in the Phase 2/3 AHEAD-MERIT study. The trial pairs the agent with pembrolizumab against pembrolizumab alone in patients with HPV16-positive recurrent or metastatic head and neck cancer.
When the first analysis landed, the combination missed its initial dual primary endpoint: a statistically significant improvement in progression-free survival over the antibody by itself could not be demonstrated. That is not the end of the story, however. The evaluation continues, with overall survival serving as the second primary endpoint. Under the predefined study design, a statistically significant advantage on that measure can still deliver a positive overall result.
BioNTech does not treat the first-endpoint miss as conclusive proof of failure, according to Handelsblatt and Reuters, precisely because the survival data remain outstanding. That distinction matters: for now, the program's clinical and commercial fate hinges on a readout that has yet to arrive.
BMO Turns More Skeptical
Not everyone is waiting with the same composure. On Wednesday, confidence at BMO Capital Markets dimmed, with analysts at the firm taking a more skeptical view of the overall survival prospects following the endpoint miss, according to media reports.
Should investors sell immediately? Or is it worth buying BioNTech?
Setbacks of this kind are hardly rare in late-stage clinical development, but they frequently translate into delays for developers. Until final survival data are in hand, the program carries an extra layer of uncertainty — which in turn raises the stakes for the remaining candidates in the portfolio, if the scientific platform is to be underpinned for the long haul.
Tübingen Plant to Close After Deal Collapses
Running alongside the pipeline developments, BioNTech is reorganizing its site structure. As Handelsblatt reported, the company plans to shut its Tübingen facility. An offer from an investor consortium around Peter Löw worth up to EUR 20 million failed to produce an agreement. The group had proposed taking on 500 employees, but the negotiations fell apart.
The consolidation of capacity marks a shift toward leaner cost structures now that the pandemic-era windfall has faded.
Insider Sales Follow a Pre-Set Script
Mandatory disclosures about securities transactions also drew attention. Form 4 filings documented sales of ordinary shares by CEO Ugur Sahin, with tranches including 17,000, 21,000, 24,000, 27,000, 36,209 and 72,000 shares.
The disposals were executed under a trading plan pursuant to US Rule 10b5-1, established back in June 2026. Such arrangements automate executive transactions according to pre-defined criteria, meaning the sales proceed independently of news flow or the company's operational interim results — a long-term scheduled disposition rather than a reaction to events.
A Stock Waiting for a Catalyst
On the trading floor, the mix of clinical hurdles and structural overhaul shows up in a hesitant valuation. Despite an unchanged solid capital position, forceful impulses capable of carrying a broad upward move are currently absent.
The shares closed yesterday at EUR 80.45, leaving the stock roughly 24 percent below its 52-week high of EUR 105.80. In German trading the paper has changed hands at EUR 80.60. What could shift the mood are reliable clinical milestones that confirm the group's long-term potential in oncology — and those, for the moment, remain pending.
Ad
BioNTech Stock: New Analysis - 16 October
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
